Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR2 | O43603 | 4/20 | 0.49 |
| ▸ | GALR1 | P47211 | 4/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13761487 | 0.99 | TRPV1 (0.48) | GALR2GALR1MAPK1HSD17B10KDM4E | |
| SCHEMBL3878708 | 0.92 | GALR2 (0.49) | GALR2GALR1TRPV1HSD11B1 | |
| SCHEMBL3883969 | 0.92 | GALR2 (0.47) | GALR2GALR1TRPV1HSD11B1 | |
| SCHEMBL3881863 | 0.91 | GALR2 (0.49) | GALR2GALR1TRPV1HSD11B1 | |
| SCHEMBL3882725 | 0.91 | TRPV1 (0.47) | GALR2GALR1MAPK1HSD17B10TRPV1 | |
| SCHEMBL3942023 | 0.90 | GALR2 (0.47) | GALR2GALR1TRPV1HSD11B1 | |
| SCHEMBL3878981 | 0.90 | GALR2 (0.48) | GALR2GALR1TRPV1HSD11B1 | |
| SCHEMBL3878375 | 0.89 | GALR2 (0.46) | GALR2GALR1TRPV1HSD11B1 | |
| SCHEMBL13766201 | 0.89 | HSD17B10 (0.44) | GALR2GALR1MAPK1HSD17B10KDM4E | |
| SCHEMBL3880752 | 0.88 | TRPV1 (0.47) | GALR2GALR1MAPK1HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | GPR174, GPR68, PPARG | GALR2 171/4885GALR1 270/4885MAPK1 3202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.